台股 » 個股 » 中裕 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

中裕

(4147)
可現股當沖
  • 股價
    84.9
  • 漲跌
    ▲0.4
  • 漲幅
    +0.47%
  • 成交量
    471
  • 產業
    上櫃 生技醫療類股
  • 318人加入追蹤

    立即追蹤

  • 本地時間:14:30

     
中裕 (4147)籌碼相關-美好-基隆 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

美好-基隆 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2025/01/082100.252101.0097.2008720.00%
2025/01/0700.00291.9192.70-2649-0.30%
2025/01/0600.00390.5389.80-3611-0.49%
2024/12/260.185.1200.0086.300.15920.01%
2024/12/240.183.0000.0082.900.15970.02%
2024/12/2300.00183.5082.90-1612-0.16%
2024/12/1800.00182.1082.90-1626-0.16%
2024/12/111.188.0100.0086.001.16210.18%
2024/12/061.187.55288.9087.60-0.9573-0.16%
2024/12/03184.80185.7084.3005290.00%
2024/12/02184.2000.0084.2015240.19%
2024/11/290.183.90183.4084.30-0.9524-0.17%
2024/11/26183.9000.0083.9015390.19%
2024/11/2500.00183.5085.00-1543-0.18%
2024/11/20178.60179.9079.0005150.00%
2024/11/1900.00178.9078.60-1523-0.19%
2024/11/14181.2000.0081.0015360.19%
2024/11/13181.7000.0081.7015370.19%
2024/11/12182.00182.5082.5005350.00%
2024/11/11281.30282.3082.4005330.00%
2024/10/30183.10282.8581.40-1601-0.17%
2024/10/2900.00181.0080.90-1588-0.17%
2024/10/28184.2000.0081.0015840.17%
2024/10/2500.00182.2081.40-1567-0.18%
2024/10/1700.00175.5075.00-1591-0.17%
2024/10/07177.5000.0077.8016290.16%
2024/10/0400.00178.2078.20-1629-0.16%
2024/09/27180.2000.0080.1016490.15%
2024/09/26182.8000.0080.2016500.15%
2024/09/25183.80185.6082.2006510.00%
2024/09/2000.00180.8080.90-1653-0.15%
2024/09/05179.2000.0079.2017110.14%
2024/09/02186.40187.6085.3007530.00%
2024/08/30185.7000.0086.4017500.13%
2024/08/2900.00184.4084.40-1734-0.14%
2024/08/2800.00184.1083.70-1733-0.14%
2024/08/2300.00181.4081.00-1752-0.13%
2024/08/21180.20181.1080.9007600.00%
2024/08/20279.7500.0080.0027540.26%
2024/08/19179.6000.0079.4017520.13%
2024/08/08175.00176.7076.7007830.00%
2024/08/0700.00175.5075.60-1779-0.13%
2024/07/2900.00183.6082.60-1741-0.13%
2024/07/22191.00189.9087.1007450.00%
2024/07/19190.3000.0086.5017270.14%
2024/07/1700.00288.1088.10-2713-0.28%
2024/07/160.186.1000.0085.600.17200.01%
2024/07/1100.00885.2084.90-8765-1.05%
2024/07/0900.00184.0084.10-1810-0.12%
2024/07/08486.9500.0086.0048290.48%
2024/07/04387.0300.0086.9038890.34%
2024/07/03187.8000.0087.4019530.10%
2024/07/01290.0000.0090.2021,0960.18%
2024/06/2600.00188.7089.50-11,123-0.09%
2024/06/2400.00186.7086.70-11,128-0.09%
2024/06/2000.00890.1089.90-81,128-0.71%
2024/06/18892.00391.8092.0051,1400.44%
2024/06/1700.00191.5091.50-11,153-0.09%
2024/06/1400.00191.0090.90-11,158-0.09%
2024/06/13691.0200.0091.0061,1640.52%
2024/06/1200.001191.0091.00-111,174-0.94%
2024/06/111191.00191.7091.00101,1820.85%
2024/06/0700.00590.1090.10-51,167-0.43%
2024/06/0500.00490.1590.30-41,237-0.32%
2024/06/0400.00189.9089.50-11,317-0.08%
2024/06/03489.6800.0089.6041,3860.29%
2024/05/29589.1000.0089.1051,5110.33%
2024/05/24187.001087.0087.20-91,869-0.48%
2024/05/2200.00188.5088.50-12,100-0.05%
2024/05/21189.10190.3088.0002,1230.00%
2024/05/201087.2000.0087.20102,1300.47%
2024/05/15186.6000.0086.4012,2110.05%
2024/05/1400.00188.4087.40-12,250-0.04%
2024/05/13186.2000.0086.5012,2620.04%
2024/05/030.285.1000.0085.800.22,3180.01%
2024/04/2500.00182.9082.50-12,325-0.04%
2024/04/120.194.3000.0094.000.12,3390.00%
2024/04/11295.00194.2095.8012,3490.04%
2024/04/09196.20195.4096.2002,3010.00%
2024/04/08191.2000.0093.0012,2360.04%
2024/04/03189.50291.6590.60-12,195-0.05%
2024/03/21188.70189.8088.6002,0140.00%
2024/03/1300.00492.2090.90-41,947-0.21%
2024/03/082100.1500.0096.8021,8650.11%
2024/03/073103.831107.00107.5021,7970.11%
2024/03/051104.0000.00102.5011,7040.06%
2024/03/0100.001109.00109.00-11,602-0.06%
2024/02/291.2110.043110.17110.50-1.81,559-0.12%
2024/02/271114.5000.00114.0011,4130.07%
2024/02/2600.009103.00108.00-91,247-0.72%
2024/02/239102.5000.00102.5091,1070.81%
2024/02/2100.000.495.4094.80-0.41,005-0.04%
2024/02/2000.001094.4096.30-10979-1.02%
2024/02/19993.00993.4093.0009520.00%
2024/02/161091.80592.8091.6059520.52%
2024/02/1500.001291.8691.10-12963-1.25%
2024/02/051188.701190.2088.7009780.00%
中裕長效型愛滋療法2a臨床全數完成注射 今年底至明年初可獲初步結果Anue鉅亨-2024/08/30
中裕與沙國藥廠簽抗愛滋病新藥中東、北非獨家銷售合約UDN聯合新聞網-2024/03/14
中裕 相關文章